BioPorto
1.768 DKK -6.95%HC Andersen Capital receives payment from BioPorto for a DigitalIR/Corporate Visibility agreement. See disclaimer.
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read moreAnalyst
Latest videos
Financial calendar
First Quarter 2024: Strong growth in US sales of The NGAL Test
Resolutions of Annual Geneal Meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits